By Anton Paul in Miami As executive delegates return to their desks across global money centres and digest the full implications of the week, the legacy of Sibos 2026 is coming into sharp focus.

Kraig Biocraft Laboratories (OTCQB: KBLB) is making a pivotal move in its push to turn genetically engineered spider silk from a scientific breakthrough into a commercially scalable material. The ...

Equity Insider News Commentary - The global tungsten market is valued at approximately $6.66 billion in 2026 and is projected to reach about ...

U.S. Metal News News Commentary - The silver market is on track for its sixth consecutive annual deficit in 2026, according to the World Silver Survey 2026 published by The Silver Institute and Metals ...

Amid a rash of disappointing late-stage clinical study results, drug developers are smashing out some decent mid-stage success. ... Read More The post Health Check: Drug developers slug some home runs ...

IRVINE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Skyworks (Nasdaq: SWKS) today announced the successful completion of its combination with Qorvo. The close of the transaction creates a U.S.-based, ...

Securitize Corp. benefits from the SEC’s Innovation Exemption, expanding its opportunity in tokenized securities and secondary trading.

Demand for automated test equipment remains strong as customers introduce more complex silicon and memory. At the same time, the wafer fabrication equipment market is inflecting higher, providing ...

Strong Buy on Cohu, Inc.: price target raised to $95 after strong Q2 2026 results and AI/HPC pipeline to $850M. Click for this COHU stock update.

Arm's CEO cited the same customer demand figure in July and September, yet the stock reacted in completely opposite ways. What shifted between those two moments could redefine how the entire chip ...

A surprise CEO departure sent MongoDB tumbling 25% in a month while its database rivals barely flinched, and now one major Wall Street bank sees a setup that could reward patient investors.

AstraZeneca announced Phase III HICKORY findings for investigational efzimfotase alfa in 124 treatment-naïve adolescents and adults with hypophosphatasia. At week 25, the primary ...